🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Updated OS from the LAURA study shows trend for OS benefit with osi over plb continuation after cCRT: IA 54 vs NR, HR 0.81, ns (20% events); Updated A 58.8 vs 54 mo, HR 0.67, (31% events). Subsequent 3G-TKI 80% in the placebo group! #ESMOAmbassadors #ELCC25 ESMO - Eur. Oncology Suresh S. Ramalingam, MD, FASCO

Collaboration knows no borders at IASLC reception #ELCC25 - especially when there's a football table involving Italians and Portuguese s Mariana Brandao Leonardo Brunetti Giulia La Cava Filippo Gallina

🔥 In-Depths from #ELCC2025! AI + outreach = smarter LCS Dr Anouk Goudsmit & Prof Mariana Brandao on innovation in lung cancer screening. Watch now! 👀 bit.ly/3YeP1Xl #MediMix #LungCancer #AI #Screening #Oncology

🔥 In-Depths from #ELCC2025! SC > IV? Prof Mariana Brandao on SC pembrolizumab. ⏱️ 2-min injection. Same efficacy. Less burden. Watch now! 👀 bit.ly/3YeP1Xl #MediMix #LungCancer #NSCLC #Immunotherapy

Dynamic debate session on resectable NSCLC. Key points: - degree of surgical LND likely impacted outcomes in adj IO trials (consensus: requires standardization) - should the adj portion contain a diff type of IO? (No consensus! Trials ongoing, eg vaccine) Federico Cappuzzo #LCSM

Great scientific meeting this weekend in Rome, with molecular NSCLC alterations tomorrow! Federico Cappuzzo #lungcancer

Terrific afternoon sessions at #RomeLung25 - Defining and delivering integrated therapies for stage III requires collaboration across disciplines. - optimal adj duration still unknown Marina Garassino Outstanding programme Federico Cappuzzo #LorenzaLandi and #TinaCascone

Dr. Noemi Reguart discusses PD1/VEGF bispecifics in NSCLC at #RomeLung25. Many compounds in development- ivonescimab and BNT-327 furthest along. Encouraging results from HARMONi-2. Will cooperative binding and complex formation lead to better survival? Need to see full results here.

Excellent presentation on ADC in combination with immunotherapy in NSCLC by Stephen V Liu, MD at 4th International Summit of Lung Cancer in Rome 🇮🇹 Federico Cappuzzo Hossein Borghaei, DO Thomas Wu Noemi Reguart Delvys Rodriguez Abreu

Amazing explanation by Marzia Del Re, PharmD, PhD about #ADCs construction and PK&PD parameters to take into account when designing and testing these novel drugs in #cancer Assume nothing! And analyse each component of these complex & fascinating drugs EORTC #EORTC_LCG #YECIday25 OncoAlert

Excellent overview by Roger Sun on the use of imaging and radiomics in #cancer clinical trials: 🔵 Predictive & prognostic potential for IO & targeted agents 🔵 Still problems with standardization of imaging & external validation of the signatures EORTC #EORTC_LCG OncoAlert

Three formidable days dedicated to clinical research, collaboration and mentoring come to an end. It was a pleasure to host the EORTC Lung Cancer Group in Genova!🇮🇹 Anne-Marie Dingemans Benjamin Besse Jordi Remon Mariana Brandao Corinne Faivre-Finn Roberto Ferrara Matthias Guckenberger OncoAlert

Join us in Milan for hot topic debates and critical analysis of trials in thoracic oncology ! Biagio Ricciuti, MD, PhD Roberto Ferrara Julia Rotow MD Narjust Florez, MD, FASCO Benjamin Besse Mariana Brandao Rafeh Naqash, MD Marina Garassino

🚨 New insights in #RETpositive #LungCancer: RET+ NSCLC often express MET & TROP2, moderately HER3 & EGFR, and rarely HER2. ➡️ Multiple membrane targets may co-exist 🧬 Dynamic changes post-treatment — fresh biopsy recommended 💡 Supports ADC & bispecific antibody trials

Clinical case submissions are now open for the Yin & Yang Lung Cancer Masterclass! July 11-12, 2025 in Milan, Italy <40? Oncologist, surgeon, or rad onc? Submit by June 15! Submit a case on one of the topics: 1️⃣ Multimodal Rx (resectable/LA NSCLC) 2️⃣ Adjuvant EGFR/ALK+ NSCLC 3️⃣

How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, Clarissa Mathias moderates a discussion with Guilherme Harada and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC. 🎧 Listen now: bit.ly/VTBport

Sarah Waliany, MD, MS presented treatm options and sequences in ALK+ resected NSCLC. Dr. Antonio Calles 🫁🚭 Mariana Brandao fighting on the role of adjuvant chemo in oncogene+ NSCLC at #Yin&Yang Lung Cancer Masterclass 2025. Nice perspectives on the ideal ALINA trial Mihaela Aldea Biagio Ricciuti, MD PhD

Fantastic debate b/w JessicaJLinMD & Narjust Florez, MD, FASCO at Yin & Yang Lung Ca Masterclass: 1L lorlatinib vs 1L 2G TKIs for ALK+ mNSCLC 💠Median PFS >5yrs of 1L lorla. More limited 2L+ activity especially w/o secondary mut 💠More challenging tox of lorla: neurocog AE,⬆️wt, HLD, etc

Platinum plus etoposide with durvalumab for ES-SCLC with untreated brain metastases: a multicenter, single-arm ph II trial (LOGiK2001, SPEED) in ESMO Open. icRR 67%, median icPFS 4.2 months. 50% of pts received local brain therapy at PD.esmoopen.com/article/S2059-…